T. Rowe Price Health Care ETF

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

Resona Asset Management Reduces Danaher Stake; Danaher Beats Earnings Expectations but Analysts Lower Price Target

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Stryker Agrees to Acquire Amplitude Vascular Systems for $835 Million

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

AVTX

TMED

LABU

ARKG

BMED

SBIO

IBBQ

Avalo Therapeutics, Inc. has seen its 12-month stock price target cut to $47.82, suggesting a potential upside of 144%. The average price target from 10 analysts has increased from $48.1 to $48.7, with estimates ranging from $35 to $62 per share. The consensus rating remains a "Buy" with 12 analysts recommending buys and none holding or selling. This information is based on the latest analyst forecasts and does not constitute investment advice.

TradingView

Avalo Therapeutics

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Biotechnology & Genome ETF

Blackrock Future Health ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Factset Research

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing a revenue of $19.7M and a net loss of $19.63M, reflecting a year-over-year decline in both metrics. The company achieved positive Phase 2 results for its drug abdakibart in treating hidradenitis suppurativa, supporting plans for Phase 3 trials. R&D and G&A expenses increased to prepare for pivotal trials, and the company completed a $405M follow-on offering to fund operations through 2029.

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Avalo Therapeutics, a biotech company, experienced a significant surge in its stock price to a two-year peak on Wednesday following promising outcomes related to its treatment for skin diseases. The company's stock soared amid this positive development, positioning it as a noteworthy competitor against major pharmaceutical companies like AbbVie, Novartis, and Sanofi. This breakthrough news was reported without specifying the information source.

Unusual Whales

Abbvie

NOVARTIS AG

Sanofi

Novartis AG

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

benzinga_article

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

StockTitan

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

Avalyn Pharma (AVLN) priced its upsized IPO of 16.67 million shares at $18.00, raising $300.06 million. The stock surged to $26.00 in its NASDAQ debut, marking a 44.44% gain. The company focuses on inhaled treatments for rare respiratory disorders, with leading candidates AP01 and AP02 in clinical trials. Despite the successful IPO, Avalyn reported a net loss of $85.2 million with no revenue for the previous year.

IPO Scoop

Morgan Stanley

Jefferies Financial

Evercore

Nasdaq

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

The IPO Buzz: Avalyn Pharma (AVLN) Priced Upsized IPO at $18 – Top – & Stock Pops

Avalyn Pharma Inc. has set its IPO price at $18 per share for its upcoming trading on the Nasdaq under the ticker "AVLN" starting April 30, 2026. The company plans to offer 16.67 million shares, aiming for gross proceeds of $300 million, with the offering closing on May 1, 2026.

rttnews

iShares US Healthcare Providers

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Proshares UltraShort Nasdaq Biotech

Avalyn Sets IPO Price At $18 Per Share

159615

Valo Health, Inc., based in Lexington, Massachusetts, has appointed Chris Anagnostopoulos, PhD, C.Stat, as the Chief Causal AI Officer. This newly created position will focus on advancing Valo's human causal biology platform by utilizing human data and AI for drug discovery. Dr. Anagnostopoulos will be responsible for translating extensive real-world human data into causal insights that can enhance the drug discovery process. Valo's goal is to enhance their capabilities in this area to improve the drug development process further.

China Southern Hang Seng Biotech ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Valo Health Appoints Chris Anagnostopoulos, PhD, as Chief Causal AI Officer

If You Are Buying Into the Comeback Story in UnitedHealth Stock, Buy This ETF Too

Barchart Option

iShares US Medical Devices

Simplify Health Care ETF

SPDR S&P Health

SPDR S&P Health Equip

Unitedhealth

iShares Genomics Immunology and Healthcare ETF

Leverage Shares 2X Long UNH Daily ETF

If You Are Buying Into the Comeback Story in UnitedHealth Stock, Buy This ETF Too

Wall Street analysts have initiated coverage on several stocks, including Avalo Therapeutics Inc (NASDAQ:AVTX), which received a Market Outperform rating and a price target of $52 from Citizens analyst Jason Butler. Avalo shares closed at $17.76. Other notable initiations include PayPay Corp (NASDAQ:PAYP) with an Outperform rating and a price target of $26, and Atlas Critical Minerals Corp (NASDAQ:ATCX) with a Buy rating and a price target of $13.75. Analysts have changed their outlooks on various stocks, reflecting a mix of upgrades and downgrades.

Atlas Critical Minerals

PayPay

This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

T. Rowe Price Health Care ETF(TMED.US)

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News